Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Joseph Constable was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Apr 30
The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026 The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 29, 2026. 공시 • Jul 10
The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million. The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.608879 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 13,387,853
Price\Range: AUD 0.01
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,000,000
Price\Range: AUD 0.01
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 39,500,000
Price\Range: AUD 0.01
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,000,000
Price\Range: AUD 0.01
Transaction Features: Rights Offering 공시 • Mar 25
The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million. The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 0.65 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 65,000,000
Price\Range: AUD 0.01
Transaction Features: Subsequent Direct Listing 공시 • Mar 14
The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025 The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 28, 2025. Board Change • Sep 03
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • May 29
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Margaret Hardin was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • May 24
The Hydration Pharmaceuticals Company Limited Announces Board Change, Effective 25 May 2024 The Hydration Pharmaceuticals Company Limited announced that further to the change of Board composition announced on 23 April 2024, and as part of the Company's continuous review of Board skills and composition, Mr. Nick Berry will be appointed as a non-executive Director, effective 25 May 2024. Mr. Nick Berry's appointment as non-executive director will be effective following the resignation of Mr. George Livery on 25 May 2024. Nick Berry brings over 19 years of experience in the Australian finance industry, specialising in equity and debt capital markets, mergers and acquisitions and strategic planning. With a proven track record in raising capital and structuring and negotiating complex financial transactions, Nick has demonstrated extensive expertise and leadership in the field. He previously served as an Executive Director at Nomura Australia and is currently a Director of PURE Asset Management Pty Ltd. Nick holds a Master of Engineering (MEng) from the University of Bath and is a Member of the Australian Institute of Company Directors. Reported Earnings • Mar 01
Full year 2023 earnings released: US$0.04 loss per share (vs US$0.065 loss in FY 2022) Full year 2023 results: US$0.04 loss per share (improved from US$0.065 loss in FY 2022). Revenue: US$10.0m (up 10% from FY 2022). Net loss: US$8.10m (loss narrowed 24% from FY 2022). New Risk • Mar 01
New major risk - Negative shareholders equity The company has negative equity. Total equity: -US$358k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$5.7m free cash flow). Shares are highly illiquid. Negative equity (-US$358k). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Market cap is less than US$10m (AU$4.24m market cap, or US$2.76m). 공시 • Feb 22
The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024 The Hydration Pharmaceuticals Company Limited, Annual General Meeting, May 07, 2024. New Risk • Sep 21
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$8.3m free cash flow). Shares are highly illiquid. Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Market cap is less than US$10m (AU$9.97m market cap, or US$6.40m). Reported Earnings • Sep 05
First half 2023 earnings released: US$0.022 loss per share (vs US$0.026 loss in 1H 2022) First half 2023 results: US$0.022 loss per share (improved from US$0.026 loss in 1H 2022). Revenue: US$5.30m (up 28% from 1H 2022). Net loss: US$3.53m (loss narrowed 17% from 1H 2022). 공시 • Aug 29
The Hydration Pharmaceuticals Company Limited Announces Resignation of Gretta van Riel as Non-Executive Director, Effective September 26, 2023 The Hydration Pharmaceuticals Company Limited announced that Ms. Gretta van Riel has resigned as a Non-Executive Director of the Company, effective from the 26th of September. New Risk • Aug 13
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$9.8m free cash flow). Shares are highly illiquid. Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (AU$7.12m market cap, or US$4.62m). Minor Risk Shareholders have been diluted in the past year (21% increase in shares outstanding). 공시 • Aug 12
The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. The Hydration Pharmaceuticals Company Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 33,333,337
Price\Range: AUD 0.045
Discount Per Security: AUD 0.0027
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Reported Earnings • Mar 01
Full year 2022 earnings released: US$0.07 loss per share (vs US$0.12 loss in FY 2021) Full year 2022 results: US$0.07 loss per share. Revenue: US$9.10m (up 49% from FY 2021). Net loss: US$10.6m (loss widened 19% from FY 2021). 공시 • Feb 08
The Hydration Pharmaceuticals Company Limited Announces Executive Changes The Hydration Pharmaceuticals Company Limited announced the appointment of Victoria Nadalin as Company Secretary upon the resignation of Carlie Hodges, effective 8 February 2023. Victoria is a practising corporate and commercial lawyer and is completing a Graduate Diploma in Applied Corporate Governance and Risk Management with the Governance Institute of Australia.